ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL628
CHEMBL628
Compound Name PENTOXIFYLLINE
ChEMBL Synonyms PENTOXIFYLLINE | TRENTAL | TRENTAL 400 | BL 191 | PENTOXIL | TRENTAL 100 | OXPENTIFYLLINE | NEOTREN MR
Max Phase 4 (Approved)
Trade Names TRENTAL | TRENTAL 400 | PENTOXIFYLLINE | NEOTREN MR | PENTOXIL | TRENTAL 100
Molecular Formula C13H18N4O3

Additional synonyms for CHEMBL628 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CN1C(=O)N(CCCCC(=O)C)C(=O)c2c1ncn2C
Standard InChI InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(1 ...
Download InChI
Standard InChI Key BYPFEZZEUUWMEJ-UHFFFAOYSA-N

Sources

  • AstraZeneca Deposited Data
  • British National Formulary
  • Curated Drug Metabolism Pathways
  • Curated Drug Pharmacokinetic Data
  • DrugMatrix
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL628

Molecule Features

CHEMBL628 compound icon
Drug Type:Natural Product-derived Rule of Five:Y First In Class:N Chirality:Achiral Molecule Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
3',5'-cyclic phosphodiesterase inhibitor 3',5'-cyclic phosphodiesterase FDA PubMed PubMed
Adenosine A2 receptor antagonist Adenosine A2 receptor FDA PubMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Acute Kidney InjuryD058186HP:0001919Acute kidney injury2ClinicalTrials
Enterocolitis, NecrotizingD020345EFO:0003928necrotizing enterocolitis2ClinicalTrials
Hepatitis, AlcoholicD006519EFO:1001345Hepatitis, Alcoholic3ClinicalTrials
Hepatopulmonary SyndromeD020065EFO:1001346Hepatopulmonary Syndrome1ClinicalTrials
Nephrotic SyndromeD009404EFO:0004255nephrotic syndrome3ClinicalTrials
PancreatitisD010195EFO:0000278pancreatitis0ClinicalTrials
Wounds and InjuriesD014947EFO:0000546injury2ClinicalTrials
Biliary AtresiaD001656Orphanet:30391Biliary atresia2ClinicalTrials
Breast NeoplasmsD001943EFO:0003869breast neoplasm2ClinicalTrials
Cardiovascular DiseasesD002318EFO:0000319cardiovascular disease4ATC
EndometriosisD004715EFO:0001065endometriosis3ClinicalTrials
Leishmaniasis, CutaneousD016773EFO:0005046cutaneous Leishmaniasis2ClinicalTrials
Carcinoma, Non-Small-Cell LungD002289EFO:0003060non-small cell lung carcinoma2ClinicalTrials
LeishmaniasisD007896EFO:0005044Leishmaniasis2ClinicalTrials
Malaria, FalciparumD016778EFO:0007444Plasmodium falciparum malaria2ClinicalTrials
Ductus Arteriosus, PatentD0043742ClinicalTrials
Fatty LiverD005234HP:0001397Hepatic steatosis2ClinicalTrials
Head and Neck NeoplasmsD006258EFO:0004284upper aerodigestive tract neoplasm2ClinicalTrials
Brachial Plexus NeuropathiesD020516EFO:1000844brachial plexus neuropathy3ClinicalTrials
Brain DiseasesD001927EFO:0005774brain disease2ClinicalTrials
Crohn DiseaseD003424EFO:0000384Crohn's disease0ClinicalTrials
FibrosisD005355EFO:0006890fibrosis2ClinicalTrials
Muscular Dystrophy, DuchenneD020388Orphanet:98896Duchenne muscular dystrophy1ClinicalTrials
Depressive DisorderD003866EFO:0003761unipolar depression2ClinicalTrials
Diabetic NephropathiesD003928EFO:0000401diabetic nephropathy2ClinicalTrials
NeoplasmsD009369EFO:0000311cancer2ClinicalTrials
Non-alcoholic Fatty Liver DiseaseD065626EFO:1001249non-alcoholic steatohepatitis2ClinicalTrials
Sarcoidosis, PulmonaryD017565DOID:13406pulmonary sarcoidosis2ClinicalTrials
Coronary Artery DiseaseD003324EFO:0000378coronary artery disease2ClinicalTrials
GliomaD005910EFO:0000326central nervous system cancer1ClinicalTrials
HIV InfectionsD015658EFO:0000764HIV infection1ClinicalTrials
Renal Insufficiency, ChronicD051436EFO:0003884chronic kidney disease2ClinicalTrials
Liver Cirrhosis, BiliaryD008105EFO:1001486primary biliary cirrhosis2ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-LymphomaD054198EFO:0000220acute lymphoblastic leukemia2ClinicalTrials

Clinical Data

ClinicalTrials.gov PENTOXIFYLLINE
The Cochrane Collaboration PENTOXIFYLLINE

Metabolites for CHEMBL628

Open in full screen

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL628. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL6007 Transient receptor potential cation channel subfamily A member 1 Homo sapiens 0.935
CHEMBL302 Adenosine A2a receptor Rattus norvegicus 0.914
CHEMBL2304404 Adenosine A1 receptor Cavia porcellus 0.838
CHEMBL4028 Thromboxane-A synthase Rattus norvegicus 0.827
CHEMBL5185 Glutamate racemase Helicobacter pylori J99 0.767
CHEMBL318 Adenosine A1 receptor Rattus norvegicus 0.701



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL2605 Adenosine A2a receptor Cavia porcellus 1.000
CHEMBL2304404 Adenosine A1 receptor Cavia porcellus 1.000
CHEMBL302 Adenosine A2a receptor Rattus norvegicus 1.000
CHEMBL318 Adenosine A1 receptor Rattus norvegicus 1.000
CHEMBL6007 Transient receptor potential cation channel subfamily A member 1 Homo sapiens 0.915
CHEMBL2592 Adenosine A2b receptor Rattus norvegicus 0.843
CHEMBL255 Adenosine A2b receptor Homo sapiens 0.835
CHEMBL4028 Thromboxane-A synthase Rattus norvegicus 0.350
CHEMBL5185 Glutamate racemase Helicobacter pylori J99 0.258
CHEMBL325 Histone deacetylase 1 Homo sapiens 0.202

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
278.3 278.1379 0.19 5 78.89 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
7 0 0 7 0 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
- .5 -.15 -.15 2 20 0.73

Structural Alerts

There are 4 structural alerts for CHEMBL628. To view alerts please click here.

Compound Cross References

ATC C - CARDIOVASCULAR SYSTEM
C04 - PERIPHERAL VASODILATORS
C04A - PERIPHERAL VASODILATORS
C04AD - Purine derivatives
C04AD03 - pentoxifylline

ChemSpider ChemSpider:BYPFEZZEUUWMEJ-UHFFFAOYSA-N
DailyMed pentoxifylline
PubChem SID: 11111613 SID: 11111614 SID: 124881066 SID: 144203774 SID: 170465384 SID: 26719692 SID: 26747196 SID: 50085870 SID: 50105176 SID: 85231180 SID: 857899 SID: 90341235
Wikipedia Pentoxifylline

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL628



ACToR 6493-05-6
BindingDB 10850
Brenda 138805 209606
ChEBI 7986
DrugBank DB00806
DrugCentral 2099
eMolecules 715662
EPA CompTox Dashboard DTXSID7023437
FDA SRS SD6QCT3TSU
Guide to Pharmacology 7095
Human Metabolome Database HMDB0014944
IBM Patent System A8A4E872F5604DFC1895B55DF7A4B8DC
KEGG Ligand C07424
LINCS LSM-3285
Mcule MCULE-9951939936
MolPort MolPort-001-823-263
NIH Clinical Collection SAM001247011
Nikkaji J3.419C
PDBe PNX
PharmGKB PA450864
PubChem 4740
PubChem: Drugs of the Future 81044341
PubChem: Thomson Pharma 14799544
SureChEMBL SCHEMBL34039
ZINC ZINC000001530776

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/BYPFEZZEUUWMEJ-UHFFFAOYSA-N spacer
spacer